{
    "root": "35bc5ff5-8e78-54cf-e063-6394a90ae3c2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "bupropion hydrochloride",
    "value": "20250522",
    "ingredients": [
        {
            "name": "ETHYLCELLULOSE (100 MPA.S)",
            "code": "47MLB0F1MV"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHYLENE CHLORIDE",
            "code": "588X2YUY0A"
        },
        {
            "name": "POLYETHYLENE GLYCOL 1450",
            "code": "OJ4Z5Z32L4"
        },
        {
            "name": "POVIDONE K90",
            "code": "RDH86HJV5Z"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O"
        }
    ],
    "indications": "bupropion hydrochloride extended-release tablets ( xl ) aminoketone antidepressant , indicated : treatment major depressive disorder ( mdd ) ( 1.1 ) prevention seasonal affective disorder ( sad ) ( 1.2 )",
    "contraindications": "general : increase dose gradually reduce seizure risk . ( 2.1 , 5.3 ) periodically reassess dose need maintenance treatment . ( 2.2 ) major depressive disorder starting dose : 150 mg daily . usual target dose : 300 mg daily ( 2.2 ) 4 days , may increase dose 300 mg daily . ( 2.2 ) seasonal affective disorder initiate treatment autumn prior onset seasonal depressive symptoms . ( 2.3 ) starting dose : 150 mg daily . usual target dose : 300 mg daily . ( 2.3 ) one week , may increase dose 300 mg daily . ( 2.3 ) continue treatment winter season . ( 2.3 ) hepatic impairment moderate severe hepatic impairment : 150 mg every day ( 2.6 ) mild hepatic impairment : consider reducing dose and/or frequency dosing . ( 2.6 , 8.7 ) renal impairment consider reducing dose and/or frequency dosing . ( 2.7 , 8.6 )",
    "warningsAndPrecautions": "bupropion hydrochloride extended-release tablets , usp ( xl ) 300 mg pink , round biconvex coated tablet imprinted '189 ' black ink one side plain side . follows . ndc : 70518-4343-00 packaging : 30 1 blister pack store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . protect light . bupropion hydrochloride extended-release tablets , usp ( xl ) may odor . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients seizure disorder . bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients current prior diagnosis bulimia anorexia nervosa higher incidence seizures observed patients treated bupropion hydrochloride extended-release tablets ( xl ) [ ( 5.3 ) ] . bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients undergoing abrupt discontinuation alcohol , benzodiazepines , barbiturates , antiepileptic drugs [ ( 5.3 ) ( 7.3 ) ] . maois ( intended treat psychiatric disorders ) concomitantly bupropion hydrochloride extended-release tablets ( xl ) within 14 days discontinuing treatment bupropion hydrochloride extended-release tablets ( xl ) contraindicated . increased risk hypertensive bupropion hydrochloride extended-release tablets ( xl ) used concomitantly maois . bupropion hydrochloride extended-release tablets ( xl ) within 14 days discontinuing treatment maoi also contraindicated . starting bupropion hydrochloride extended-release tablets ( xl ) patient treated reversible maois linezolid intravenous methylene blue contraindicated [ ( 2.9 ) , ( 5.4 ) ( 7.6 ) ] . bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients known hypersensitivity bupropion ingredients bupropion hydrochloride extended-release tablets ( xl ) . anaphylactoid/anaphylactic stevens-johnson syndrome reported [ ( 5.8 ) ] .",
    "indications_original": "Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant, indicated for: treatment of major depressive disorder (MDD) ( 1.1 ) prevention of seasonal affective disorder (SAD) ( 1.2 )",
    "contraindications_original": "General: Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) Periodically reassess the dose and need for maintenance treatment. ( 2.2 ) Major Depressive Disorder Starting dose: 150 mg once daily. Usual target dose: 300 mg once daily ( 2.2 ) After 4 days, may increase the dose to 300 mg once daily. ( 2.2 ) Seasonal Affective Disorder Initiate treatment in the autumn prior to onset of seasonal depressive symptoms. ( 2.3 ) Starting dose: 150 mg once daily. Usual target dose: 300 mg once daily. ( 2.3 ) After one week, may increase the dose to 300 mg once daily. ( 2.3 ) Continue treatment through the winter season. ( 2.3 ) Hepatic Impairment Moderate to severe hepatic impairment: 150 mg every other day ( 2.6 ) Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. ( 2.6 , 8.7 ) Renal Impairment Consider reducing the dose and/or frequency of dosing. ( 2.7 , 8.6 )",
    "warningsAndPrecautions_original": "Bupropion hydrochloride extended-release tablets, USP (XL) 300 mg are pink, round biconvex coated tablet imprinted with '189' in black ink on one side and plain on the other side. They are as follows.\n                  \n                  NDC: 70518-4343-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.\n                  Bupropion hydrochloride extended-release tablets, USP (XL) may have an odor.\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder.\n                       Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride extended-release tablets (XL)\n  \n   [see Warnings and Precautions (\n   \n    5.3)]\n  \n   .\n \n  \n                       Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs\n  \n   [see Warnings and Precautions (\n   \n    5.3) and Drug Interactions (\n   \n    7.3)]\n  \n   .\n \n  \n                       The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (XL) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (XL) are contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (XL) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated\n  \n   [see Dosage and Administration (\n   \n    2.9), Warnings and Precautions (\n   \n    5.4) and Drug Interactions (\n   \n    7.6)]\n  \n   .\n \n  \n                       Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL). Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported\n  \n   [see Warnings and Precautions (\n   \n    5.8)]."
}